[Association of Crohn's disease with aryl hydrocarbon receptor gene polymorphisms and haplotypes]

C Q Wu, S G Cao, X P Xia

  • 1Department of Gastroenterology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

Zhonghua Nei Ke Za Zhi
|January 12, 2018
PubMed

Insights

Aryl hydrocarbon receptor (AhR) gene variations, specifically rs2158041, may influence Crohn's disease (CD) risk and characteristics. Certain AhR haplotypes, CCG and CTG, are linked to increased and decreased CD risk, respectively.

Area of Science:

  • Genetics
  • Gastroenterology
  • Immunology

Background:

  • Crohn's disease (CD) is a chronic inflammatory bowel disease with complex genetic underpinnings.
  • The aryl hydrocarbon receptor (AhR) plays a role in immune regulation and gut homeostasis.
  • Investigating the association between AhR polymorphisms and CD susceptibility is crucial for understanding disease pathogenesis.

Purpose of the Study:

  • To examine the relationship between aryl hydrocarbon receptor (AhR) gene polymorphisms and haplotypes and Crohn's disease (CD) susceptibility in a Han Chinese population.
  • To determine if specific AhR variants influence the clinical and pathological characteristics of CD.

Main Methods:

  • Case-control study involving 310 CD patients and 573 healthy controls.
  • Genotyping of three AhR single nucleotide polymorphisms (SNPs): rs10249788, rs2158041, and rs2066853.
  • Analysis of allelic and genotypic frequencies, linkage disequilibrium, and haplotype associations using logistic regression and Haploview software.

Main Results:

  • The variant allele (T) and genotype (CT+TT) of AhR rs2158041 were significantly decreased in CD patients compared to controls (P=0.009 and P=0.003, respectively).
  • Lower frequencies of rs2158041 variant allele and genotype were observed in CD patients with terminal ileum involvement and constricting disease.
  • Haplotype analysis revealed an increased frequency of CCG (P=0.039) and a decreased frequency of CTG (P=0.047) in CD patients compared to controls.

Conclusions:

  • The rs2158041 polymorphism in the AhR gene may be associated with altered risk, location, and behavior of Crohn's disease.
  • The AhR haplotype CCG might increase the risk of developing CD, while the CTG haplotype may confer a protective effect.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...